RETIGABINE (EZOGABINE)
Retigabine
(ezogabine in the USA) was approved as an anti-seizure drug in Europe and the
USA in 2010. It is a potassium-channel facilitator and unique in its mechanism
of action. Absorption is not affected by food and kinetics are linear; drug
interactions are mini-mal. Clinical trials demonstrated efficacy in partial
seizures, and approval is for the adjunctive treatment of partial-onset
seizures in adults. Doses range from 600 to 1200 mg/day, with 900 mg/day
expected to be the median. The current dosage form requires three-times-per-day
administration, and the dose must be titrated in most patients. Most adverse
effects are dose-related and include dizziness, somnolence, blurred vision,
confusion, and dysarthria. Bladder dysfunction, mostly mild and related to the
drug’s mechanism of action, was observed in 8-9% of patients in the clinical
trials.
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2024 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.